JW (Cayman) Therapeutics Co Ltd
HKEX:2126

Watchlist Manager
JW (Cayman) Therapeutics Co Ltd Logo
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Watchlist
Price: 1.73 HKD 1.17% Market Closed
Market Cap: 719.9m HKD

Intrinsic Value

The intrinsic value of one JW (Cayman) Therapeutics Co Ltd stock under the Base Case scenario is 7.12 HKD. Compared to the current market price of 1.73 HKD, JW (Cayman) Therapeutics Co Ltd is Undervalued by 76%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
7.12 HKD
Undervaluation 76%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
JW (Cayman) Therapeutics Co Ltd

Valuation History Unavailable

Historical valuation for JW (Cayman) Therapeutics Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

JW (Cayman) Therapeutics Co Ltd
HKEX:2126
CN
Biotechnology
Market Cap
718.9m HKD
IPO
Nov 3, 2020
CN
Biotechnology
Market Cap
718.9m HKD
IPO
Nov 3, 2020
Price
HK$false
EPS
ÂĄfalse
Company Overview
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about JW (Cayman) Therapeutics Co Ltd
Financials
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
JW (Cayman) Therapeutics Co Ltd

Balance Sheet Decomposition
JW (Cayman) Therapeutics Co Ltd

Current Assets 808.7m
Cash & Short-Term Investments 757.4m
Receivables 7.2m
Other Current Assets 44.1m
Non-Current Assets 871.7m
PP&E 275.5m
Intangibles 583m
Other Non-Current Assets 13.2m
Efficiency

Free Cash Flow Analysis
JW (Cayman) Therapeutics Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
JW (Cayman) Therapeutics Co Ltd

Revenue
158.2m CNY
Cost of Revenue
-80.9m CNY
Gross Profit
77.3m CNY
Operating Expenses
-536.3m CNY
Operating Income
-459m CNY
Other Expenses
-131.6m CNY
Net Income
-590.6m CNY
Fundamental Scores

Profitability Score
Profitability Due Diligence

JW (Cayman) Therapeutics Co Ltd's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Positive Gross Profit
ROIC is Increasing
30/100
Profitability
Score

JW (Cayman) Therapeutics Co Ltd's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

JW (Cayman) Therapeutics Co Ltd's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
49/100
Solvency
Score

JW (Cayman) Therapeutics Co Ltd's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
JW (Cayman) Therapeutics Co Ltd

There are no price targets for JW (Cayman) Therapeutics Co Ltd.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

JW (Cayman) Therapeutics Co Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for JW (Cayman) Therapeutics Co Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest
What is the Intrinsic Value of one JW (Cayman) Therapeutics Co Ltd stock?

The intrinsic value of one JW (Cayman) Therapeutics Co Ltd stock under the Base Case scenario is 7.12 HKD.

Is JW (Cayman) Therapeutics Co Ltd stock undervalued or overvalued?

Compared to the current market price of 1.73 HKD, JW (Cayman) Therapeutics Co Ltd is Undervalued by 76%.

Back to Top